| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6239ff6fe13e938cdf6854d9e1d1dee7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-35 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5415 |
| filingDate |
2013-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e8ebd205faafa2be6dceca6613be80c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e2c314d59296815773df3754d9661ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8786daa785a1fa4ad8163c500ec116bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9771d12282a976a86fd409478297a6b9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_564ec1feb3cb5d97d42afca06b287455
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c1b6ef9f727c3b2538b2dbd5f496c50 |
| publicationDate |
2014-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2767275-A1 |
| titleOfInvention |
Nortriptyline, haloperidol or prochlorperazine edisylate for use in the treatment of tuberculosis as well as two screening methods |
| abstract |
The present invention relates to a compound capable of killing mycobacteria by activating host cellular mechanisms for use in treating tuberculosis, wherein the compound is selected from the group consisting of nortriptyline, haloperidol and prochlorperazine edisylate (PE). Furthermore, the present invention relates to a pharmaceutical composition comprising the compound of the invention, and optionally a pharmaceutically acceptable carrier. The invention further relates to a method of treating tuberculosis as well as a method of identifying a lead compound for the treatment of tuberculosis. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113218848-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113218848-B |
| priorityDate |
2013-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |